GCNT1 and prostate carcinoma: This study shows overexpression of GCNT1 in prostate cancer cells modifies cell surface glycosylation and leads to increased levels of core 2 O-glycan structures, including upregulation of the poly-N-acetyllactosamine chain (which serves as a scaffold for terminal modifications such as the tumour-associated glycan sLeX).